Submissions
2
2 included · 0 excluded
Overall compliance
80%
Mean across audit criteria
Fully compliant cases
50%
1 of 2 included
Status
Preview
Preview Audit · Cycle 1
Project summary
NICE NG5: Medicines optimisation; NHS structured medication review guidance; STOPP/START criteria version 3
Eligible adults receiving multiple regular medicines should have a structured medicines review that documents medicine burden, high-risk medicines, anticholinergic burden, renal function, falls risk, medicine indication, patient/carer involvement, STOPP/START or equivalent appropriateness criteria, actions and follow-up.
- Cycle
- Preview Audit · Cycle 1
- Standard
- Structured review, actions and follow-up documented
- Location field
- Ward / Location
- Status
- Preview
Workflow
Standard Lazomis QIP tabs
Clinical safety
Standing principles
- This tool supports, but does not replace, clinical judgement.
- Follow local polypharmacy, medicines optimisation and deprescribing policy; seek pharmacist, geriatrician or specialist input where needed.
- High-risk medicines, renal impairment, falls risk and high anticholinergic burden should trigger appropriate senior/pharmacy review and monitoring.
- Audit identifiers should be pseudonymised — do not record patient-identifiable data.
Resources
Recommended Lazomis QI resources and national guidance
NICE NG5, NHS England structured medication review guidance, NHS Specialist Pharmacy Service deprescribing resources and STOPP/START v3 are collected in the Resources tab, alongside recommended Lazomis QI guides.